PRECOS Appoints Dr. Neil Rotherham as Chairman
Posted: 4 October 2010 | | No comments yet
Preclinical Oncology Services Limited (PRECOS), announces the appointment of Dr. Neil Rotherham as chairman of the PRECOS board…
Preclinical Oncology Services Limited (PRECOS), announces the appointment of Dr. Neil Rotherham as chairman of the PRECOS board...
Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service with a specific focus on oncology, announces the appointment of Dr. Neil Rotherham as chairman of the PRECOS board. Dr. Rotherham has over 20 years’ leadership experience in the life sciences, medical, pharmaceutical and biopharmaceutical sectors. His extensive business experience and industry knowledge will be invaluable in the development and growth of the company going forward.
Dr. Rotherham was responsible for developing and growing ClinPhone plc, one of Nottingham’s and Europe’s most successful clinical technology businesses.
As co-founder and managing director of ClinPhone, Dr. Rotherham led the company from a two-person start-up in 1993 to a 500-person global venture that was listed on the London Stock Exchange in 2006. Dr. Rotherham left the business after bringing through a management team to run the business subsequent to going public.
Prior to co-founding ClinPhone, Dr. Rotherham worked in the pharmaceutical industry on medicine development for Boots Pharmaceuticals. His prior qualification in medicine and training as a hospital physician will undoubtedly be beneficial to PRECOS as it looks to establish its range of innovative services within the global healthcare industry. Dr. Rotherham brings a wealth of experience in growing businesses providing services to drug development companies.
“PRECOS combines the innovation of one of the Country’s leading universities with the scientific background and expertise of multi-disciplinary scientists.” said Dr. Rotherham. “This places the company in an optimal position to deliver specialist services, backed by significant industry expertise and cutting-edge technology, to help both pharmaceutical and biotechnology companies develop new anti-cancer drugs.” He continues, “PRECOS occupies a niche in global pre-clinical R&D working with unique patient-relevant models closely reflecting the patient situation. Tumour development can be monitored in real-time, allowing companies to concentrate efforts on those compounds most likely to have a therapeutic effect in patients with cancer.”
Professor Sue Watson, Chief Scientific Officer of PRECOS, comments, “We are delighted to welcome Neil as chairman of the PRECOS board. Neil’s unparalleled experience and business acumen will be crucial in directing the company’s growth. This appointment reinforces the ambition and potential of PRECOS to exploit the growing cancer therapy market. We are extremely excited to develop our expertise in cancer drug development into medicines with real patient benefits.”
PRECOS offers the advantages of both academic and industrial scientific approaches to deliver a unique skill set to the global healthcare industry, providing high quality, solutions-driven, tailored services. Its extensive experience as a specialised research and development service has made PRECOS a trusted and preferred partner for some of the world’s leading oncology research companies.